Malaria clinical trials
The registry lists 1,184 studies for Malaria across more than 10 countries. 79 are recruiting or about to start. 883 of them are mainly about Malaria (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 2 narrower conditions too, such as Malaria, Falciparum: 1,426 studies, 108 open.
ClinicalTrials.gov finds 1,490 studies for Malaria. How that becomes 1,184 here
This page counts the studies the registry files under Malaria, and those it files under no condition that list Malariathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,490Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −242Filed under a narrower condition, counted on its own pageMalaria, Falciparum 182 · Malaria, Vivax 56
- −17List Malaria as a condition, but the registry did not file them under itMost often written as “Cerebral Malaria” (4), “Malaria in Pregnancy” (3), and “Malaria Parasitaemia” (2). The registry filed them under other conditions only, most often Malaria, Cerebral (6) and Anemia (5).
- −47Match it another way38 name it in the title, 3 in a keyword, and 6 by a synonym or other text the search reads.
- 1,184The count on this page47 of them list Malaria in their own words; the registry filed them under no condition.
Get an email when these change. Save the Malaria studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (111) · London School of Hygiene and Tropical Medicine (105) · University of Oxford (82) · Medicines for Malaria Venture (53) · GlaxoSmithKline (41) · Centers for Disease Control and Prevention (32) · University of California, San Francisco (31) · U.S. Army Medical Research and Development Command (30)
What is being tested here
Drugs under test in Malaria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Piperaquine | 5 | 30 | 63 |
| Artenimol | 4 | 28 | 57 |
| Amodiaquine | 2 | 16 | 43 |
| Chloroquine | 1 | 13 | 40 |
| PfSPZ Challenge | 1 | 0 | 13 |
| Tafenoquine | 1 | 0 | 10 |
| Ivermectin | 1 | 7 | 10 |
| CHAD63 | 1 | 0 | 9 |
| NITD 609 | 1 | 0 | 7 |
| Acetaminophen | 1 | 2 | 6 |
Drug classes tested here Antimetabolites 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- May 2027FocaL Mass Drug Administration for Vivax Malaria Elimination · Phase 3 · University of California, San Francisco
- May 2027Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP) · Phase 3 · Grant Dorsey, M.D, Ph.D.
- Nov 2026Non-invasive Malaria Diagnostic Data Collection in Ethiopia · Foundation for Innovative New Diagnostics, Switzerland
- Nov 2026Post-discharge Malaria Chemoprevention Implementation Trial in Benin · Institut de Recherche Clinique du Benin
- Nov 2026Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana · Noguchi Memorial Institute for Medical Research
- Dec 2026MDA and Targeted Control Against Plasmodium Carriage in the Sahel · Institut de Recherche pour le Developpement
- Dec 2026Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad · Epicentre
- Dec 2026L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) · Liverpool School of Tropical Medicine
- Dec 2026R21/MM Dosing, Presentations, and Preservatives · University of Oxford
- Jan 2027Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC · Institute of Tropical Medicine, Belgium
Who these studies take
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger. 37 (73%) take children under 18. 9 (18%) are for women only and 0 (0%) for men only; 31 (61%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 18 (35%) | 18 (35%) |
| 18 | 35 (69%) | 26 (51%) |
| 30 | 35 (69%) | 27 (53%) |
| 40 | 34 (67%) | 27 (53%) |
| 50 | 29 (57%) | 25 (49%) |
| 65 | 23 (45%) | 19 (37%) |
| 75 | 19 (37%) | 15 (29%) |
| 85 | 18 (35%) | 14 (27%) |
Across all 1,184 studies, recruiting or not: 68% stop at 75 or younger and 67% at 65; 66% take children; 9% are for women only and 3% for men only; 57% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Malaria studies take
Of 93 phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 13 mo7–20 · 93 studies | 11 mo6–18 · 29 studies | 13 mo7–24 · 64 studies |
| Phase 1/2 | 18 mo8–32 · 16 studies | — | — |
| Phase 2 | 16 mo10–27 · 39 studies | — | — |
| Phase 3 | 23 mo17–31 · 50 studies | — | 23 mo20–34 · 44 studies |
| Phase 4 | 19 mo7–32 · 49 studies | — | 18 mo7–29 · 48 studies |
| Interventional, no phase | 23 mo8–33 · 101 studies | — | 23 mo11–35 · 95 studies |
| Observational | 24 mo16–44 · 93 studies | — | 23 mo13–36 · 85 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting2
Results posted1
Newly registered5
- Spatial Emanator Deployment Strategies for Malaria Control in Papua New GuineaNov 3, 2026NCT07912528
- VectorCAM: A Digital Innovation to Advance Entomological SurveillanceNov 2, 2026NCT07909746
- Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee SettingsOct 29, 2026NCT07903324
- Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and RwandaOct 27, 2026NCT07896746
- Humanitarian Evaluation of Spatial Emanators for Malaria ControlOct 21, 2026NCT07886281
Studies
Recruiting first, then most recently updated. Showing 50 of 1,184. Browse all 1,184 → or search them.
- Spatial Emanator Deployment Strategies for Malaria Control in Papua New GuineaNot yet recruitingNCT07912528Not applicable1 country
- A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum MalariaRecruitingNCT07545681Phase 22 countries
- Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding AssaysRecruitingNCT06607003Phase 11 country
- Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria InfectionNot yet recruitingNCT07859800Not applicable1 country
- Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, MaliRecruitingNCT011682711 country
- The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron DeficiencyRecruitingNCT06816524Not applicable1 country
- Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruitingNCT06862453Phase 11 country
- Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic InfectionRecruitingNCT000016451 country
- Focal Mass Drug Administration for the Prevention of Malaria in PregnancyRecruitingNCT07021430Early Phase 11 country
- Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee SettingsNot yet recruitingNCT07903324Not applicable1 country
- Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and RwandaNot yet recruitingNCT07896746
- DON in Pediatric Cerebral MalariaRecruitingNCT05478720Phase 1/21 country
- Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 YearsNot yet recruitingNCT07831226Phase 11 country
- Humanitarian Evaluation of Spatial Emanators for Malaria ControlNot yet recruitingNCT07886281Phase 41 country
- This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax MalariaNot yet recruitingNCT07430592Phase 21 country
- Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine CandidatesRecruitingNCT024713781 country
- First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy AdultsRecruitingNCT07646353Phase 11 country
- Collection of Human Biospecimens for Basic and Clinical Research Into Globin VariantsRecruitingNCT039378171 country
- Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.RecruitingNCT07758985Phase 11 country
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community TransmissionNot yet recruitingNCT07246525Phase 41 country
- Platelet-Directed Whole Blood Transfusion Strategy for MalariaRecruitingNCT05711485Not applicable2 countries
- Non-invasive Malaria Diagnostic Data Collection in EthiopiaRecruitingNCT074569691 country
- OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan SchoolchildrenNot yet recruitingNCT07798583Phase 3
- Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria ChallengeRecruitingNCT026392991 country
- Insecticide-Treated Baby Wraps for the Prevention of MalariaNot yet recruitingNCT07773350Not applicable1 country
- Community-Based Cohort Study of Hidden Malaria Infections, Diagnostic Gaps, & Mosquito Vector Dynamics in Odisha, IndiaRecruitingNCT077700481 country
- Post-discharge Malaria Chemoprevention Implementation Trial in BeninRecruitingNCT06601712Phase 41 country
- Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)RecruitingNCT077499112 countries
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy AdultsNot yet recruitingNCT07470424Phase 11 country
- R21/MM Dosing, Presentations, and PreservativesNot yet recruitingNCT07194668Phase 41 country
- PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliRecruitingNCT07675785Phase 21 country
- Surveillance of AMR in DRCRecruitingNCT068212821 country
- Integrating the Guardian Spatial Emanator Within AVENIR IINot yet recruitingNCT07712263Not applicable1 country
- Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated MalariaNot yet recruitingNCT07713602Phase 4
- Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy ParticipantsRecruitingNCT07011511Phase 11 country
- FocaL Mass Drug Administration for Vivax Malaria EliminationRecruitingNCT05690841Phase 31 country
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsRecruitingNCT07385287Phase 21 country
- Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in RwandaNot yet recruitingNCT07548021Phase 11 country
- Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in ChadRecruitingNCT07038837Phase 41 country
- Xpert® Tropical Fever Test on GeneXpert® Edge X SystemEnrolling by invitationNCT075202791 country
- Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai AdultsRecruitingNCT07257965Not applicable1 country
- A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )Not yet recruitingNCT05380388Phase 21 country
- Pregnancy Registry in MaliRecruitingNCT064683191 country
- An Ultra-short Course of Primaquine for the Radical Cure of Vivax MalariaNot yet recruitingNCT07468526Phase 34 countries
- Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella DiseaseRecruitingNCT074164611 country
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of GhanaRecruitingNCT07389057Not applicable1 country
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in AfricaRecruitingNCT06967519Phase 41 country
- Long-acting Spatial Emanators / Repellents (LASER)Not yet recruitingNCT07387341Not applicable1 country
- Severe Malaria in Remote Areas- Closing the Evidence GapEnrolling by invitationNCT068069562 countries
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country